Role of Sodium-Glucose Cotransporter 2 Inhibitors in Preventing of Renal Impairment Progression in Patients with Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is one of the leading causes of chronic kidney disease (CKD) and end-stage renal disease, requiring expensive methods of renal replacement therapy (RRT) (dialysis, kidney transplantation). Currently nephroprotective therapy is based on correction of modified factors of CKD progression and administration of drug for blockade of activity renin-angiotensin system. Actually a new group of antihyperglycaemic drugs, of sodium-glucose co-transporter type 2 inhibitors (SGLT2i) is wide spread. They help to reach good glycaemic control, along with effect ofkidney protection in T2DMpatients with CKD. Their application in these patients leads to reduction of albuminuria, slowing of progressive filtration function deterioration and eventually reduces new incidence of RRT initiation. This review presents analysis of experimental and clinical investigations of nephroprotective effects of SGLT2i.